Receive news by e-mail

#
 

Enter your e-mail in the field below to receive directly the news that appears on this page.

 

topics : related - all Explore

Shopping

Top Product

Hepatitis C: Practical, Medical, and Spiritual Guidelines for Daily Living with HCV (Hazelden Pocket Health Guide)

Compare prices

  1. 2. Healing Hepatitis C: A Patient and a Doctor on the Epidemic's Front Lines Tell You How to Recognize When You Are at Risk, Understand Hepatitis C Tests, Talk to Your Doctor About Hepatitis C, and Adv
  2. 3. HealthScouter Hepatitis: Hepatitis Treatment and Hepatitis Symptoms: Includes Hepatitis C Symptoms and Hepatitis B Symptoms
  3. 4. OSHA Bloodborne Pathogens Manual and CD, Introductory But Comprehensive OSHA (Occupational Safety and Health) Training for the Managers and Employees in ... to AIDS, HIV, Hepatitis B, and Hepatitis C
  4. 5. The Bible Cure for Hepatitis and Hepatitis C (Bible Cure Series)

Shopping Categories

  1. 1. Cell Phones
  2. 2. Smartphones
  3. 3. Digital Cameras
  4. 4. Laptop Computers
  5. 5. Processors
  6. 6. Motherboards
  7. 7. LCD Monitors
  8. 8. Graphics Cards
  9. 9. GPS
  10. 10. Digital Camcorders
  11. 11. Printers
  12. 12. Desktop Computers
  13. 13. Sedans
  14. 14. Coupes & Convertibles
  15. 15. 4x4

Wikio Shopping

  1. 1. Automotive
  2. 2. Beauty & Fragrances
  3. 3. Books
  4. 4. Car/Motorbike
  5. 5. CD
  6. 6. Clothing, Accessories & Shoes
  7. 7. Communication
  8. 8. Computers
  9. 9. DVD
  10. 10. Electronics
  11. 11. Flowers & Gifts
  12. 12. Gourmet & Foods
  13. 13. Health & Personal Care
  14. 14. Home & Garden
  15. 15. Hotels
  16. 16. Household Appliances
  17. 17. Jewelry & Watches
  18. 18. Musical Instruments
  19. 19. Sports & Outdoors
  20. 20. Toys & Baby
  21. 21. Video Games

Participate



Hepatitis C



Sort by : relevance - date - popularity
3Vote!

Prison hep C problem will cost millions, MPs told

Canadian taxpayers could be on the hook for millions of dollars in health care costs unless something is done to stop the spread of hepatitis C among injection drug users in federal prisons, a House of Commons committee heard.

3Vote!

Hepatitis C outbreak, sexually transmitted, in New York

Just came across my Email that there is a new strain of Hepatitis C among gay men in New York City. As a pathologist I really dislike Hep C. It gets lab people all the time with needle sticks, etc. I'm a lot more afraid of Hep C than of HIV. And a new strain, efficiently sexually transmitted, with rapid liver damage?

5Vote!

Lower Third Quarter Loss for Human Genome

Zacks.com submits: Human Genome Sciences, Inc. ( HGSI ) reported third quarter net loss of $49 million or 32 cents per share, in-line with the Zacks Consensus Estimate. The company reported a net loss of $74.2 million or 50 cents in the year ago quarter. The lower net loss for the quarter was primarily attributable to increased revenues from manufacturing and development services and lower operating...

4Vote!

Idera Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides Pipeline Update

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today reported financial results for the third quarter and nine months ended September 30, 2009. “We have continued development of our pipeline of drug candidates targeted to Toll-like receptors for potential applications in chronic hepatitis C virus infection and autoimmune diseases, and to support our partnered programs...

3Vote!

More Than 80 Percent Of HCV Genotype 1 Treatment-Naive Patients Achieved Sustained Virologic Response With Twice-Daily Telaprevir-Based Regimen

Tibotec announced results of a new study (VX950-C208), which showed that sustained virologic response (SVR) was achieved in more than 80 percent of treatment-naïve patients with chronic genotype 1 hepatitis C virus (HCV) who took telaprevir, administered either every 8 hours or every 12 hours, in combination with standard of care.

4Vote!

Medivir: New Phase IIa data on TMC435 In Patients with Hepatitis C Presented at the Ongoing AASLD - Meeting

STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News: Data were presented from the phase IIa trial (OPERA-1) for TMC435 at the ongoing 60th annual meeting of the American Association for the Study of Liver Diseases in Boston, USA. TMC435 is an investigational protease inhibitor, being developed by Tibotec in collaboration with Medivir, for the treatment of hepatitis C virus (HCV). Data for TMC435 in...

3Vote!

Vertex and Ironwood Drugs Fare Well in Clinical Trials, Pulmatrix Breathes in $30.2M, IRobot Launches Healthcare Unit, & More Boston-Area Life Sciences News

A number of New England’s life sciences companies had good news to report this week. —Cambridge, MA-based Vertex Pharmaceuticals (NASDAQ: VRTX) reported results from clinical trials that indicate its experimental hepatitis C drug, telaprevir, could work well for patients who haven’t responded fully to standard treatments, and could be as effective taken twice a day as [...]

4Vote!

INFORM-1 Results: Robust Antiviral Suppression Achieved with Combination of Nucleoside Analog Polymerase Inhibitor RG7128 and Protease Inhibitor RG7227

BOSTON, Nov. 3 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) and Pharmasset, Inc. (Nasdaq: VRUS) today announced results from all patient cohorts of the INFORM-1 trial, an innovative Phase 1 study of two direct-acting antiviral (DAA) compounds administered without interferon or ribavirin for the treatment of patients chronically infected with the hepatitis C virus (HCV).(i) The study, conducted...

4Vote!

Idera Pharmaceuticals Presents Preclinical Data on IMO-2125, its Lead Drug Candidate for Chronic Hepatitis C Virus Infection, at Liver Meeting 2009

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today presents preclinical data on the mechanism by which IMO-2125 was shown to induce immune activation through Toll-like Receptor 9 (TLR9). Two presentations are being made today at the 60th Annual Meeting of the American Association for the Study of Liver Diseases being held in Boston, MA. “Induction of endogenous...

4Vote!

Valeant Pharmaceuticals Highlights Taribavirin Phase IIb End of Study Data Presentation at American Association for the Study of Liver Disease (AASLD) Annual Meeting

ALISO VIEJO, Calif., Nov. 3 /PRNewswire-FirstCall/ -- Valeant Pharmaceuticals (NYSE: VRX) today announced that results from the week-72 analysis for its Phase IIb dose-finding clinical trial for taribavirin, a prodrug of ribavirin which is in development for the treatment of chronic hepatitis C in conjunction with a pegylated interferon, were presented at the American Association for the Study of Liver...

  • 0 add comment
  • share
4Vote!

Idenix Pharmaceuticals Initiates Phase II Clinical Trial of IDX184 in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV)

CAMBRIDGE, Mass., Nov. 3 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, announced today that it has initiated a Phase II clinical trial evaluating IDX184, a liver-targeted nucleotide prodrug candidate for the treatment of HCV, in combination with pegylated...

  • 0 add comment
  • share
3Vote!

Bristol-Myers Squibb And ZymoGenetics Present Final Phase 1b Results For PEG-Interferon Lambda In Hepatitis C

Bristol-Myers Squibb Company (NYSE: BMY) and ZymoGenetics, Inc. (NASDAQ: ZGEN) today presented final results from a Phase 1b clinical trial of PEG-Interferon lambda administered with ribavirin in relapsed and treatment-naïve hepatitis C virus (HCV) patients. The poster included data on 56 patients in the study. Antiviral activity was observed at all dose levels tested.

3Vote!

Twice Daily Oral Medication Shows Promise In Treating Patients With Hepatitis C

All approved therapy regimens to treat patients with hepatitis C are based on interferon, which must be injected.

3Vote!

Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), An Investigational, Once-Daily Protease Inhibitor For Hepatitis C

Schering-Plough Corporation (NYSE: SGP) reported that interim results from an ongoing Phase IIa study of narlaprevir (SCH 900518), its investigational, once-daily protease inhibitor, demonstrated potent antiviral activity in treatment-naive patients with chronic hepatitis C virus (HCV) genotype 1.

3Vote!

Combination Drugs Are The Future for Hepatitis C

Combination therapy has been a central component of treatment for certain viral diseases for more than 15 years. The benefits of combination therapy can arise from activation of multiple host pathways, suppression of mutational variants that can lead to viral escape, or perhaps both. In HIV, the benefit of combination therapy is due to suppression [...]

The 3 latest articles published by users on Hepatitis C :

4Vote!

Buy Rebetol online, Order cheap Rebetol, Order cheap Rebetol without prescription, Buy Rebetol online, Buy Rebetol no prescription

Buy Rebetol without prescription - Click Here! >>> Rebetol is used for treatment of hepatitis C infection in certain patients when used in combination with interferon. Order Rebetol at one of the trusted online pharmacies and save your money. Check Prices and Buy Rebetol Important! Free Pills with EVERY order! No prescription is needed! Safe and Secured 100% Best Customer service Click Here to Order...

3Vote!

Hepatitis C Therapy Area Pipeline Report

Hepatitis C Therapy Area Pipeline Report        - aarkstore

Hepatitis C Therapy Area Pipeline Report contains detailed information on the hepatitis c drug pipeline. This report provides insight into the pipeline status of hepatitis c drugs by company and by stage as well as a summary of the latest news and developments in this area. Scope of the report: Therapy Area Pipeline Report provides the user with real detail on drug pipelines, by company and by stage,...

3Vote!

Disease and Therapy Review: Hepatitis C

Disease and Therapy Review: Hepatitis C    - aarkstore

The Hepatitis C Disease and Therapy Review provides incidence and prevalence numbers and percentages for major countries worldwide, and an overview of treatments. Dosing information and treatment costs are provided for Peg-Intron, Pegasys, Rebetol, Copegus, and generic ribavirin capsules. General information on sales of peginterferon and ribavirin is provided. Additional Information Disease and Therapy...